LIXTE Secures U.S. Patent for Innovative Cancer Treatments
![LIXTE Secures U.S. Patent for Innovative Cancer Treatments](https://investorshangout.com/images/blog/ihnews-LIXTE%20Secures%20U.S.%20Patent%20for%20Innovative%20Cancer%20Treatments.jpg)
LIXTE’s New Patent Boosts Cancer Treatment Innovations
Patent Overview
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT and LIXTW) has recently made headlines by receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its U.S. Patent application numbered 16/467,721. This patent, titled "Oxabicycloheptanes for Modulation of Immune Response," specifically covers the combination of its groundbreaking LB-100 compound with various advanced cancer immunotherapies.
CEO Insights on the Patent Award
According to Bas van der Baan, the Chief Executive Officer of LIXTE, this new patent strengthens the company’s intellectual property portfolio. He emphasized how this achievement reflects LIXTE’s unwavering commitment to innovative research aimed at providing effective solutions for patients facing cancer challenges.
Clinical Development of LB-100
LIXTE is in the process of developing LB-100, a first-in-class lead clinical PP2A inhibitor, designed to enhance the efficacy of cancer immunotherapy. The company is currently conducting clinical trials at renowned institutions including the Netherlands Cancer Institute (NKI) and The University of Texas MD Anderson Cancer Center in Houston.
Collaboration with Leading Institutions
At NKI, LIXTE supplies LB-100, while F. Hoffmann-La Roche Ltd. contributes atezolizumab (Tecentriq), a PD-L1 inhibitor, as part of a collaborative effort called the imCORE Network. This initiative seeks to expedite research in cancer immunotherapy through academic and industry partnerships specifically focusing on patients with unresponsive metastatic colon cancer.
Further Clinical Studies at MD Anderson
In addition, another clinical trial at MD Anderson is investigating the effects of combining LB-100 with GSK’s dostarlimab-gxly, targeting treatment for ovarian clear cell carcinoma (OCCC).
Exclusive Licensing Agreement and Future Prospects
The recent patent approval follows LIXTE’s exclusive patent licensing agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI) earlier this year. This deal offers LIXTE the chance to further explore novel combination therapies that could potentially revolutionize cancer treatment paradigms.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is a clinical-stage pharmaceutical company dedicated to discovering new avenues in cancer drug development. The company is committed to developing and commercializing effective cancer therapies. Their lead clinical candidate, LB-100, has shown promising tolerance and anti-cancer activity in patients, which lays the groundwork for enhancing conventional chemotherapies and immunotherapies.
LIXTE is pioneering a new field of cancer biology known as activation lethality. The company’s comprehensive patent portfolio supports their innovative approach, with ongoing clinical trials currently targeting colon, ovarian, and sarcoma cancers.
Contact Information
For further information, LIXTE invites inquiries through the following contacts:
Email: info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Or contact Investor Relations at PondelWilkinson Inc.:
Email: pwinvestor@pondel.com
Roger Pondel: (310) 279-5965
Laurie Berman: (310) 279-5962
Frequently Asked Questions
What is the significance of LIXTE's recent patent?
The patent allows LIXTE to protect its innovative approach of combining LB-100 with new cancer immunotherapies, enhancing their research efforts.
What is LB-100?
LB-100 is LIXTE’s lead clinical compound designed to inhibit PP2A, thereby acting as a potentiator in cancer immunotherapy.
How does LIXTE collaborate with research institutions?
LIXTE partners with leading institutions like NKI and MD Anderson to conduct clinical trials utilizing their compounds in combination with existing therapies.
What are the focus areas of LIXTE's clinical trials?
LIXTE's trials focus on various cancers, including colon cancer and ovarian clear cell carcinoma, assessing the effects of LB-100 combined with other immunotherapies.
Where can I find more information about LIXTE?
More details about LIXTE and their ongoing projects can be found directly on their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Court TV Announces Exciting Fall Primetime Lineup for 2024
- Mediaspace.global Launches Changemakers' Summit for 2024
- MALK Organics Launches Almond Pumpkin Spice for Fall 2024
- Accorto Regulatory Solutions Partners with GINN for Tobacco Safety
- Carterra Ultra™: Transforming Drug Discovery with Precision
- Opus IVS DrivePro 2 Achieves Motor Top 20 Award for 2024
- Autograph Revolutionizes Sports Fandom with New Platform
- Attain Capital Welcomes Former NASA CIO Renee P. Wynn
- ICEYE and Aon Join Forces to Boost Flood and Wildfire Response
- Philadelphia Fed Initiates Search for New President Following Harker
- PhotonPharma Showcases Innovative Cancer Therapies Conference
- Blaze Mota Unveils THC-Infused Mota'lada for Everyone
- Adam Neumann and Ryan Serhant to Speak at South Florida Forum
- Unilever Secures Approval to Sell Russian Assets Amid Criticism
- Growth Prospects for Global Furniture Fittings Market Ahead
- Industrial Cooling Systems Market Set for Remarkable Growth
- Tarkett Receives Platinum Medal from EcoVadis for Sustainability
- Integra LifeSciences Prepares for 2024 Wells Fargo Event
- Gong Named Leader in Revenue Orchestration Platforms by Forrester
- Microban International Partners with CiCLO for Sustainable Textiles
- Autoinjectors Market Forecast to Reach USD 3.02 Billion by 2030
- Middie Rising: A New Narrative for Schools in Transition
- Norfolk Southern Secures Tentative Agreement with Conductors' Union
- Insider Buying: Two Stocks to Watch for Potential Gains
- Join Us for the 2024 AvaSure Symposium Celebrating Virtual Care
Recent Articles
- Carterra Ultra™: Transforming Drug Discovery with Precision
- Teamsters' Strike: Ecology Curbside Services Faces Worker Discontent
- Davidson Kempner Reveals Stake in International Paper Co.
- Exciting Premier of 'Mutual of Omaha's Wild Kingdom Protecting the Wild'
- Digital Brands Group Launches AVO: Affordable Luxury Apparel
- Tower Arch Capital Partners with ACS Manufacturing for Growth
- Labatt Blue Light Unveils Exciting Promotions for Football Season
- Tenable Unveils Enhanced Nessus for Effective Risk Management
- Revitalize Breakfast with eMeals Worth the Wake Up Recipes
- Market Volatility: Recession Fears Impact Investor Confidence
- Montway Auto Transport Celebrated as 2024 MOTOR Top 20 Winner
- The Dermatology Specialists Launch 50th Location with Free Screenings
- Summit Ridge Energy Partners with Siemens for Domestic Inverters
- SeaStar Medical Eliminates Long-Term Debt to Enhance Growth
- TruLife Collaborates with Aaron Reed to Promote His Brand
- The Casual Pint Beerstro Unveils New Franchise Opportunities
- Tower Garden's New Affiliate Marketing Model Sparks Growth
- Retail Ready Packaging Market Reaches US$ 102.2 Billion by 2032
- Denmark's Leading Pension Firm Partners with Omada for IGA
- Eisai Showcases New Cancer Research Data at ESMO 2024
- RocketReach Unveils Autopilot for Seamless Outreach Automation
- Macron's Search for a Prime Minister Amid Political Turmoil
- J.Jill Reports Strong Q2 Earnings but Cautious on Q3 Outlook
- Innovative Growth in the Plant-Based Spreads Market
- Key Stock Movements: Nvidia, Dollar Tree, Hormel Foods Update